Payment overview · 2025
General Payments
$1,468.37
61 reported records · 17 companies
Healthcare provider profile · identity verified
Jun Li
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · NEW YORK, NY · NPI 1467955336
Verified facts
What the public records show
CMS Open Payments records show Jun Li received $1,468.37 in general payments during 2025 across 61 reported records.
Travere Therapeutics, Inc. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Filspari, Gemtesa, Jardiance, Lokelma, Rayaldee, Velphoro, Veltassa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexlizet by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Velphoro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rayaldee by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Gemtesa by this doctor in 2024.
Travere Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Filspari as an associated drug or biological on 8542 records involving 2693 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Filspari by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $252.17 | 17.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.18 | 12.9% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $154.82 | 10.5% | 6 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $145.98 | 9.9% | 7 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $107.76 | 7.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.84 | 7.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.37 | 6.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.68 | 4.8% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.16 | 3.7% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $53.28 | 3.6% | 3 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $45.05 | 3.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $44.33 | 3.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.95 | 2.8% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $40.00 | 2.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.00 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.55 | 1.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.25 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,322.39 | 54 |
| Education | $145.98 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $145.98 | 7 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $124.75 | 5 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $107.76 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $105.84 | 5 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $100.37 | 4 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $94.12 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $70.68 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $54.16 | 2 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $53.28 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $44.33 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.95 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Filspari filspari |
2025 | Filspari | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 77 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 71 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 189 | exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
274 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
77 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
189 | 28 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Travere Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Filspari open payments reported associated product |
CMS Open Payments — General Payments 8542 supporting records · 2693 recipient NPIs · example record 1244395624 |
Filspari · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Allopurinol | Allopurinol | 557 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 62 |
| Vascepa | Icosapent Ethyl | 313 | 61 |
| Losartan Potassium | Losartan Potassium | 301 | 68 |
| Farxiga | Dapagliflozin Propanediol | 274 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 44 |
| Calcitriol | Calcitriol | 220 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 216 | 38 |
| Sevelamer Carbonate | Sevelamer Carbonate | 207 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 43 |
| Famotidine | Famotidine | 189 | 41 |
| Velphoro | Sucroferric Oxyhydroxide | 189 | 28 |
| Finasteride | Finasteride | 187 | 34 |
| Kerendia | Finerenone | 180 | 37 |
| Nifedipine Er | Nifedipine | 166 | 38 |
| Potassium Citrate Er | Potassium Citrate | 157 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 28 |
| Tradjenta | Linagliptin | 96 | 19 |
| Calcium Acetate | Calcium Acetate | 88 | 19 |
| Lokelma | Sodium Zirconium Cyclosilicate | 77 | 29 |
| Retacrit | Epoetin Alfa-Epbx | 72 | 20 |
| Rayaldee | Calcifediol | 71 | 12 |
| Myrbetriq | Mirabegron | 66 | 15 |
| Rybelsus | Semaglutide | 55 | suppressed |
| Gabapentin | Gabapentin | 53 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 50 | suppressed |
| Carvedilol | Carvedilol | 48 | suppressed |
| Hydrocortisone | Hydrocortisone | 48 | 23 |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 16 |
| Prosol | Parenteral Amino Acid 20% No.1 | 45 | suppressed |
| Furosemide | Furosemide | 44 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 12 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 36 | suppressed |
| Gemtesa | Vibegron | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 27 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 25 | 18 |
| Filspari | Sparsentan | 25 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | 13 |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Auryxia | Ferric Citrate | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | suppressed |
| Renvela | Sevelamer Carbonate | 13 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,468.37 · 61 records | Travere Therapeutics, Inc. | ACCRUFER, BENLYSTA, Fabhalta, Filspari, GEMTESA, IBSRELA, JARDIANCE, JYNARQUE, LOKELMA, NEXLETOL, PURIFIED CORTROPHIN GEL, RAYALDEE, TARPEYO, TAVNEOS, VELPHORO, Vanrafia, Veltassa | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Filspari play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error